Bob Iger’s Return to Disney is Under Threat by Trian Proxy Vote: 3 Things Investors Need to Be Aware of
The return of Bob Iger to the Disney throne was highly anticipated, and for the most part, well-received. DIS is up more than 22% in the past year and recent earnings reports have suggested that Iger is steering the ship in the right direction. The stock is up more than 33% through 2024. However, one activist investor group has [...]
Humana Heads 15% Lower on Concern of Rising Medicare Rates: Should You Sell HUM?
Yesterday, the Centers for Medicare & Medicaid Services (CMS) shared their plans for federal payments to Medicare Advantage plans, and Humana (HUM) has taken a hit on the news. The stock is down 15% so far Tuesday morning. CMS first disclosed these plans back in January. At the time, Humana warned that should the outlined proposal pass, it would [...]
UPS Wins Over U.S. Postal Service as Air Cargo Provider, Replacing FedEx: Is it Time to Buy UPS?
United Parcel Service, or UPS (UPS), will officially replace FedEx as the United States Postal Service’s primary air cargo provider. This comes after FedEx and USPS failed to agree on new contract terms, which were set to expire later this year on September 29th. FedEx wanted to negotiate a better deal, and ultimately, ended up walking away. The two [...]
Market Recap: Mixed Performance as March Ends on Wall Street
Monday: Economic Data Weighs on Market Sentiment The week started with a downturn as investors grappled with upcoming economic data releases. The Dow, S&P500, and Nasdaq all recorded losses, slipping by 0.4%, 0.3%, and 0.3%, respectively. Tuesday: Mixed Data Leads to Afternoon Declines Tuesday saw stocks slipping further as investors reacted to a mixed bag of economic indicators. The [...]
Walgreens is Still Struggling With Profitability After Q2 Earnings Miss: Should You Sell WBA?
Shares of Walgreens Boots Alliance (WBA) are relatively flat this morning after the company reported second-quarter earnings that have analysts and investors alike concerned about profits and the long-term viability of the company’s business model. Last quarter, we wrote about Walgreens cutting their quarterly dividend and the fallout that ensued - including removal from the Dow Jones Industrial Average. [...]
Merck Spikes After FDA Approval, Sends Competitors Reeling
Merck (MRK) received US FDA approval on Tuesday after the market’s close for Winrevair to treat pulmonary arterial hypertension (PAH), causing the stock to climb 4.6% pre-market. The company’s market cap is around $332.7 billion, indicating any notable movement is a result of a significant event, so the approval demonstrates a pretty big win for the medical giant. Let’s [...]
